Home for the holidays? So are COVID, flu and the stomach bug.

Everyone's home for the holidays — and so are the germs. It's possible sickness could be knocking on the door ...
PharmiWeb

FDA Approves Genentech’s Lunsumio VELO™ for Subcutaneous Use in Relapsed or Refractory Follicular Lymphoma

Lunsumio VELO reduces administration time from 2-4 hours to approximately one minute –– Availability of Lunsumio VELO allows ...

COVID Cases Are Rising Again as Flu Surges. Know These Symptoms and How to Protect Yourself

COVID-19 infections are rising again across the U.S. Here's which symptoms to look for and how to protect yourself over the ...

What to Know About Norovirus

Given the vomiting and diarrhea, the biggest risk with norovirus is dehydration, which can turn a short-term illness into a ...
University of Utah Health

Why Self-Treating with Antibiotics Kits Can Be Risky

Thinking about using an at-home antibiotic kit? Before you do, learn why self-treating could put your health—and the ...

ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer

AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been granted Breakthrough Therapy Designation (BTD) in the US for adult patients with HER2-positive early breast cancer ...